Kala Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Kala Pharmaceuticals's estimated annual revenue is currently $11.6M per year.
- Kala Pharmaceuticals received $110.0M in venture funding in October 2018.
- Kala Pharmaceuticals's estimated revenue per employee is $129,111
- Kala Pharmaceuticals's total funding is $506.4M.
- Kala Pharmaceuticals's current valuation is $66.2M. (January 2022)
Employee Data
- Kala Pharmaceuticals has 90 Employees.
- Kala Pharmaceuticals grew their employee count by 1% last year.
Kala Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director, Account Management | Reveal Email/Phone |
2 | VP, Biologics R&D | Reveal Email/Phone |
3 | Director, National Accounts, 2019 & 2020 National President's Club Mauna Kea Award Winner | Reveal Email/Phone |
4 | Director, Supply Chain | Reveal Email/Phone |
5 | Senior Director, Quality Control | Reveal Email/Phone |
6 | Director, Optometric Relationships | Reveal Email/Phone |
7 | Chairman/CEO | Reveal Email/Phone |
8 | Territory Sales Manager | Reveal Email/Phone |
9 | Regional Sales Leader | Reveal Email/Phone |
10 | Regional Sales Leader | Reveal Email/Phone |
Kala Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Kala Pharmaceuticals?
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. For more information, please visit Kala's website at www.kalarx.com.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Security,Wind Power
$506.4M
Total Funding
90
Number of Employees
$11.6M
Revenue (est)
1%
Employee Growth %
$66.2M
Valuation
N/A
Accelerator
Kala Pharmaceuticals News
InvestorsObserver is giving Kala Pharmaceuticals Inc (KALA) an Analyst Rating Rank of 27, meaning KALA is ranked higher by analysts than 27%...
Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for...
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update. Published: Mar 29, 2022. -- Achieved $11.2...
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of ...
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial -- -- Kala expects to init ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.1M | 90 | 5% | N/A |
#2 | $9M | 90 | 5% | N/A |
#3 | $9M | 90 | -6% | N/A |
#4 | $24.6M | 91 | 12% | N/A |
#5 | $15.5M | 91 | 6% | N/A |
Kala Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-03-15 | $6.2M | Undisclosed | Lux Capital, Polaris Venture Partners | Article |
| 2013-03-01 | $11.5M | A | Crown Venture Fund LLC | Article |
| 2014-04-24 | $22.5M | B | Ysios Capital | Article |
| 2016-04-14 | $68.0M | C | Longitude Capital | Article |
| 2018-10-03 | $110.0M | Undisclosed | Athyrium Capital Management | Article |